

Please amend claims 27 and 30, as shown below. A complete listing of the claims, including their current status, is set forth below.

1-25. **(Cancelled)**

26. **(Previously presented)** A recombinant ING2 protein encoded by the contiguous polynucleotide sequence of nucleotides 120-845 of the nucleic acid set forth in SEQ ID NO:7.

27. **(Currently amended)** A recombinant ING2 protein, comprising an amino acid sequence having at least 95% sequence identity to the contiguous sequence set forth in SEQ ID NO:8, wherein said recombinant ING2 protein increases ~~transcription from a p53-binding site-controlled~~ **activity of a promoter having a p53 binding site** when introduced into a mammalian cell.

28. **(Cancelled)**

29. **(Previously presented)** A recombinant ING2 protein, consisting essentially of the contiguous amino acid sequence set forth SEQ ID NO:8.

30. **(Currently amended)** The recombinant ING2 protein of claim 29, wherein said ING2 protein increases ~~transcription from a p53-binding site-controlled~~ **activity of a promoter having a p53 binding site** when introduced into a mammalian cell.

31. **(Cancelled)**

32. **(Previously presented)** The isolated protein of claim 27, wherein said isolated protein has the contiguous amino acid sequence set forth in SEQ ID NO:8.